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Purpose: To determine the long-term efficacy of the anti-tumor necrosis factor (TNF) agents, 
infliximab (IFX) and adalimumab (ADA), in pediatric luminal Crohn's disease (CD) by 
performing a systematic literature review.
Methods: An electronic search was performed in Medline, Embase, and the Cochrane Library 
from inception to September 26, 2019. Eligible studies were cohort studies with observation 
periods that exceeded 1 year. Studies that reported time-to-event analyses were included. 
Events were defined as discontinuation of anti-TNF therapy for secondary loss of response. 
We extracted the probabilities of continuing anti-TNF therapy 1, 2, and 3 years after initiation.
Results: In total, 2,464 papers were screened, 94 were selected for full text review, and 13 
studies (11 on IFX, 2 on ADA) met our eligibility criteria for inclusion. After 1 year, 83–97% 
of patients were still receiving IFX therapy. After 2 and 3 years the probability of continuing 
IFX therapy decreased to 67–91% and 61–85%, respectively. In total, 5 of the 11 studies 
subgrouped by concomitant medication consistently showed that the probabilities of 
continuing IFX therapy in patients with prolonged immunomodulator use were higher than 
those in patients on IFX monotherapy.
Conclusion: This review of real-world evidence studies confirms the long-term therapeutic 
benefit of IFX therapy in diverse cohorts of children with luminal CD. Moreover, it supports 
the view that combination therapy with an immunomodulator prolongs the durability of IFX 
therapy in patients who previously failed to recover following first-line therapy. The limited 
number of time-to-event studies in patients on ADA prevented us from drawing definite 
conclusions about its long-term efficacy.
Keywords: Infliximab; Adalimumab; Survival analysis; Systematic review; Treatment 
outcome; Pediatrics; Crohn disease
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Long-Term Efficacy of Anti-Tumor 
Necrosis Factor Agents in Pediatric 
Luminal Crohn's Disease: A Systematic 
Review of Real-World Evidence 
Studies
INTRODUCTION
Crohn's disease (CD) is an immune-mediated chronic relapsing disorder that affects the 
gastrointestinal tract. International guidelines recommend that treatment of children with 
active luminal CD should follow a “step-up approach” [1,2].
First line induction therapy is either corticosteroids (to a maximum of 40 mg/day with gradual 
dose tapering) or exclusive enteral nutrition (for 6 to 8 weeks). Maintenance therapy is 
commonly started at the same time as induction therapy and includes standardized doses of 
mercaptopurine (1–1.5 mg/kg/day), azathioprine (2–2.5 mg/kg/day), or methotrexate (15 mg/m2/
week). Anti-tumor necrosis factor (TNF) therapy in children with luminal CD is usually indicated 
after failure of conventional therapy or when immunosuppressive therapies are poorly tolerated.
Following the publication of major landmark randomized controlled trials that reported that 
infliximab (IFX) [3] and adalimumab (ADA) [4] can induce and maintain clinical remission in 
pediatric patients, the use of these medications has dramatically increased. Although these 
randomized controlled trials (RCTs) had high internal validity, their formal methodology 
puts severe constraints on the generalizability to real-world practice. Another drawback is 
that they had a relatively brief observation period with limited follow-up.
In contrast, observational (or real-world evidence) studies, may have greater generalizability 
to clinical practice because of the use of more diverse patient cohorts and generally longer 
follow-up periods. We aimed to determine the long-term efficacy of IFX and ADA in pediatric 
luminal CD by performing a systematic review of cohort studies.
MATERIALS AND METHODS
Eligibility criteria
Eligible studies were prospective and retrospective cohorts that followed patients for more than 
1 year and reported time-to-event outcomes. Events were defined as a discontinuation of anti-
TNF therapy for secondary loss of response. Secondary loss of response refers to patients who 
responded to induction therapy, but subsequently lost response during maintenance treatment. 
We accepted studies that recorded the Physician's Global Assessment (PGA) of disease activity, 
as well as studies that used the Pediatric Crohn's Disease Activity Index (PCDAI).
We narrowed our search to studies that exclusively included patients younger than 18 years 
and were published in English. Papers that were only presented in conferences in the form of 
an abstract, or those that exclusively focused on patients with perianal or fistulizing CD were 
excluded. Studies that evaluated the efficacy of anti-TNF agents after bowel resection were 
also excluded.
Information sources, identification, and selection of studies
We searched for studies published in Medline, Embase, and the Cochrane Library from 
inception to September 26, 2019. The search strategies for each of the electronic databases 
are shown in Table 1.
The search results were imported into EndNote X9.2 for de-duplication [5], and subsequently 
imported in Rayyan, an online screening tool for systematic reviews [6]. One reviewer 
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(HvR) performed the first selection of studies on the basis of title and abstract. The full 
text manuscript of each potentially eligible study was then obtained. Two authors (HvR and 
PFvR) independently appraised full text articles against the predefined inclusion criteria. 
Disagreements were resolved by discussion.
Data extraction
The following characteristics were extracted from each selected study: First author, year of 
publication, country of origin, cohort definition, observation period, median follow-up time, 
cohort size, age at study baseline, median time from diagnosis to start of study medication, 
reason for initiating anti-TNF, induction and maintenance scheme, application of dose 
escalation and interval shortening, and concomitant medication.
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Table 1. Search Strategy per Electronic Database From Inception to September 2019
PubMed
(“Crohn Disease”[Mesh] OR “Pediatric Crohn's disease” [Supplementary Concept] OR crohn*[tiab])
AND
(“Child”[Mesh] OR “Adolescent”[Mesh] OR “Infant”[Mesh] OR “Pediatric Crohn's disease” [Supplementary 
Concept] OR child*[tiab] OR infan*[tiab] OR adolescen*[tiab] OR pediatric*[tiab] OR paediatric*[tiab] OR 
teen*[tiab] OR youth*[tiab])
AND
(“Infliximab”[Mesh] OR “Adalimumab”[Mesh] OR “Tumor Necrosis Factor-alpha/antagonists and inhibitors”[Mesh] 
OR adalimumab[tiab] OR infliximab[tiab] OR remicade[tiab] OR MAb cA2[tiab] OR monoclonal antibody cA2[tiab] 
OR biologic*[tiab] OR anti-TNF*[tiab] OR antiTNF*[tiab] OR anti-tumor necrosis factor[tiab] OR anti-tumour 
necrosis factor[tiab] OR TNF alpha block*[tiab] OR TNFalpha block*[tiab] OR tumor necrosis factor alpha 
inhibitor*[tiab] OR tumour necrosis factor alpha inhibitor*[tiab] OR tnf alpha inhibitor*[tiab] OR tumor necrosis 
factor alpha antagonist*[tiab] OR tumour necrosis factor alpha antagonist*[tiab] OR TNF block*[tiab] OR TNF 
antagonist*[tiab] OR TNF inhibit*[tiab] OR tumor necrosis factor antagonist*[tiab] OR tumour necrosis factor 
antagonist*[tiab] OR tumor necrosis factor block*[tiab] OR tumour necrosis factor block*[tiab] OR tumor necrosis 
factor inhibit*[tiab] OR tumour necrosis factor inhibit*[tiab])
AND
(“Clinical Trial” [Publication Type] OR “Controlled Clinical Trials as Topic”[Mesh] OR “Cohort Studies”[Mesh] 
OR “Survival Analysis”[Mesh] OR “Time Factors”[Mesh] OR over time[tiab] OR random*[tiab] OR trial[ti] OR 
cohort[tiab] OR prospectiv*[tiab] OR retrospectiv*[tiab] OR follow-up[tiab] OR followup[tiab] OR followed[tiab] 
OR longitudinal[tiab] OR longterm[tiab] OR long-term[tiab] OR survival anal*[tiab] OR kaplan-meier[tiab] OR 
hazard[tiab] OR cox[tiab] OR time-to-event[tiab]))
Embase
(‘Crohn disease’/exp OR crohn*:ab,ti)
AND
(‘child’/exp OR ‘adolescent’/exp OR (child* OR infan* OR adolescen* OR pediatric* OR paediatric* OR teen* OR 
youth*):ab,ti))
AND
(‘infliximab’/exp OR ‘adalimumab’/exp OR (adalimumab OR infliximab OR remicade OR ‘MAb cA2’ OR ‘monoclonal 
antibody cA2’ OR biologic* OR ‘anti-TNF*’ OR antiTNF* OR ‘anti-tumor necrosis factor’ OR ‘anti-tumour necrosis 
factor’ OR (TNF OR TNFalpha OR tnfα OR ‘tumor necrosis factor’ OR ‘tumour necrosis factor’) NEXT/3 (inhibitor* OR 
antagonist* OR block*):ab,ti))
AND
(‘clinical study’/exp OR ‘follow-up’/exp OR ‘cohort analysis’/exp OR ‘survival analysis’/exp OR ‘proportional hazards 
model’/exp OR ‘time factor’/exp OR ‘Kaplan Meier method’/exp OR ‘time to event’/exp OR (‘over time’ OR random* 
OR cohort OR prospectiv* OR retrospectiv* OR ‘follow-up’ OR followup OR followed OR longitudinal OR longterm 






(child* OR infan* OR adolescen* OR pediatric* OR paediatric* OR teen* OR youth*)
AND
(adalimumab OR infliximab OR remicade “MAb cA2” OR “monoclonal antibody cA2” OR biologic* OR (anti NEXT 
TNF*) OR antiTNF* OR “anti-tumor necrosis factor” OR “anti-tumour necrosis factor” OR (TNF OR TNFalpha OR tnfα 
OR “tumor necrosis factor” OR “tumour necrosis factor”) NEAR/3 (inhibitor* OR antagonist* OR block*))
Finally, we extracted time-to-event curve data, as described by Tierney et al. [7] to estimate 
the probability of continuing biological therapy 1, 2, and 3 years after initiation of anti-TNF 
therapy. Pooling of time-to-event data was greatly jeopardized due to heterogeneity between 
studies and was therefore not performed.
RESULTS
Study selection
This review includes results of electronic searches up to September 26, 2019. In total, 2,464 
study titles were screened, of which 94 were selected for full text review (Fig. 1) and 81 were 
excluded for not meeting the eligibility criteria. A total of 13 papers were ultimately included 
in the final analysis.
Study characteristics
The study characteristics of the included studies are presented in Table 2. Eleven cohort 
studies evaluated patients who were following IFX therapy [8-18], while the other two studies 
described patients who were following ADA therapy [19,20]. Two of the eleven studies 
on IFX had a prospective design [8,14], while the remainder were retrospective in nature 
[9-13,15-18]. All studies were published in the last 10 years, and represent daily practices in 
North America, Europe, Australia, Israel, and South Korea. In one study, CD patients with 
perianal involvement were excluded from analysis [12], while in the other twelve studies, 
perianal involvement varied from 3% [11] to 65% [15]. The cohort size varied between 47 [13] 
and 502 patients [14], and the median observation period was 1.0 to 3.5 years. The median 
time from diagnosis to the start of IFX therapy was between 1 month [15] and 1.8 years [9], 
and from diagnosis to the start of ADA therapy was between 15.7 months [20] and 4.7 years 
[19]. Patients who received IFX therapy had not been previously exposed to anti-TNFs, while 
all patients who received ADA therapy had previously failed, or had experienced adverse 
reactions to, IFX [19,20]. In ten cohort studies, a secondary loss of response was defined as a 
deterioration of PCDAI or PGA [8-10,12,14-17,19,20]. In one study, a combination of clinical, 
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Full-text articles assessed for eligibility
(n=94)








Fig. 1. Flow diagram of the systematic literature search. Reasons for exclusion at the last stage (*) included an 
observation period shorter than 1 year, adult patients, language other than English, case mix of ulcerative colitis 
and Crohn's disease, unacceptably high proportion lost-to-follow-up, no time-to-event analysis, randomized 
controlled trial or case-series, mix of infliximab and adalimumab therapy.
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Table 2. Characteristics of included studies (n=13)
Study characteristics Patient characteristics Treatment regimen Time-to-event analysis
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[median time 
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Infliximab
Hyams et al., 





128 20% 12.7 yr  
[9 mo]
Failure to reach 
remission on CS
Standard 32% DE CS 52% Deterioration 
of PGA and 




93%, 78%, 67%17% IS IM 90%





25 mo  
(IQR 13–40)
152 20% 15.0 yr  
[1.8 yr]
Failure to reach 
or maintain 
remission on 
CS or IM (97%); 
Upfront (3%)




of PGA and 




87%, 67%, 61%†36% IS
Gouldthorpe  





1.5 yr  
(range 0.3–5.8)
71 39% 14.4 yr  
[in cohort from 
2007 onwards: 
54 wk]
Failure to reach 
or maintain 
remission on CS 
or EEN
Standard - IM 79% Deterioration 
of PGA and 





Subcohort on IM: 
94%, 72%, 72%†
Subcohort not on 
IM: 83%, 65%, 
57%†
Vahabnezhad 





157 3% 13 yr  
[11 mo]
Failure to reach 
or maintain 
remission on 
CS or IM (85%); 
Upfront (15%)
Standard 20% DE IM/CS 65% Physician's 




88%, 80%, 76%†25% 
DE+IS
Church et 





1 mo  
(IQR 12–36)
195 0% 13.9 yr  
[19 mo]
Failure to reach 
or maintain 
remission on IM 
(72%); Upfront 
(28%)
Standard 25% DE IM 38% Deterioration of 
PCDAI or PGA and 





46% IS Subcohort on IM: 
97%, 94%, 92%†
Subcohort not on 
IM: 92%, 82%, 
75%†







2.8 yr  
(IQR 1.6–4.4)
47 17% 12.9 yr  
[1.0 yr]
Failure to reach 
or maintain 
remission on 
first line therapy; 
Fistulising 
disease; up front
Standard 28% DE 
and/or IS




CS 38%  
(at start)
• PCDAI
• CRP or FC
• Endoscopy
or small bowel 
imaging, and 
decision to cease 
further anti-TNF 
administration
Grossi et al., 





502 14% 13.3 yr  
[55% ≤12 mo; 
45% >12 mo]
Failure to reach 
or maintain 
remission on CS 
or IM
Standard 29% DE IM (<6 mo): 
29%
Deterioration 
of PGA and 





4% IS IM (>6 mo): 
39%
Subcohort on 





IM ≤6 mo: 70%, 
65%, 60%†
Subcohort not on 
IM: 82%, 68%, 
60%†
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(n=31): age at 














- Partial EN 
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Deterioration 
of PCDAI and 






(continued to the next page)
biochemical, and endoscopic deterioration was used [13], and in two studies the reason to 
discontinue anti-TNF therapy was not specified [11,18].
Findings
1. Probability of continuing infliximab therapy at 1, 2, and 3 years
In ten of eleven studies, the indication to start IFX therapy was failure to reach 
remission on corticosteroids or exclusive enteral nutrition, or to maintain remission on 
immunomodulators. Upfront IFX therapy was evaluated in one group of Korean pediatric 
patients [15]. A starting dose of 5 mg/kg at weeks 0, 2, and 6 was the standard induction 
regimen in all studies, followed by subsequent 8-weekly infusions during the maintenance 
126https://pghn.org https://doi.org/10.5223/pghn.2020.23.2.121
Long-Term Efficacy of Anti-TNF in Pediatric Crohn's Disease
Study characteristics Patient characteristics Treatment regimen Time-to-event analysis











Median age at 
start anti-TNF 
[median time 
from diagnosis to 
anti-TNF]












1, 2, and 3 years 
after initiation
Dupont–Lucas 




until LOR or 
transfer to 
adult care
248 24% 14.8 yr  
[0.9 yr]
Failure to reach 
or maintain 
remission on CS 
or IM
Standard 6% DE IM 62% Deterioration 
of PGA and 





19% IS CS 53% Subcohort on 





on IM or ≤6 mo: 
92%, 83%, 78%†
Cheng et al., 





2.1 yr  
(IQR 1.1–3.2)
113 55% 14.1 yr  
[19 mo]
Failure to reach 
or maintain 
remission on IM 
(81%), IM-naïve 
(19%)
Standard 56% DE 
and/or IS
IM 64% Deterioration of 
PCDAI or PGA and 
decision to cease 
further anti-TNF 
administration
Total cohort: not 
reported
CS 38% Subcohort on IM: 
96%, 88%, 83%†
Subcohort not 
on IM: 91%, 72%, 
61%†
deBruyn et al., 




86 wk  
(IQR 44–139)




remission on IM 
91%
Standard 15.2% DE At start: IM 
68%
Physician's 









Rosh et al.,  





115 21% 15.8 yr  
[4.7 yr]
Failure to reach 
remission on 
IFX or adverse 
reactions to IFX 
(95%); failure to 
reach remission 








2% DE CS 38% Deterioration of 
PCDAI or PGA and 






eow (85%), ew 
(12%), unknown 
(3%)
23% IS IM 64%
Cozijnsen et 




53 36% 11 yr  
[median duration 
of IFX therapy: 
15.7 mo]
No response or 
LOR to IFX
ADA at W0/W2: 
<40 kg: 40/20 




IM 60% Deterioration of 
PCDAI or PGA and 












TNF: tumor necrosis factor, DE: dose-escalation, IS: interval shortening, LOR: loss of response, IQR: interquartile range, IFX: infliximab, CS: corticosteroids, IM: 
immunomodulator, EEN: exclusive enteral nutrition, ADA: adalimumab, EN: enteral nutrition, AZA: azathioprine, PGA: Physician's Global Assessment, PCDAI: 
Paediatric Crohn's Disease Activity Index, CRP: C-reactive protein, FC: faecal calprotectin.
*Standard induction and maintenance scheme is IFX (5 mg/kg) at W0, W2, and W6, then 8-weekly. †Probability data manually extracted from time-to-event curves.
Table 2. (Continued) Characteristics of included studies (n=13)
phase. Reactive dose escalations (up to 10 mg/kg) and/or interval shortening for secondary 
loss of response were performed in all but two studies. In an Australian study, [10] 
government regulations precluded a dose escalation, while in the Korean study [15] dose or 
interval adjustments were not mentioned.
Fig. 2A shows that 1 year after the initiation of IFX therapy the probability of still receiving 
IFX was between 83% [13] to 97% [10,12]. Two years after the initiation of IFX therapy the 
probability of still receiving IFX was between 67% [9] and 91% [18]. Three years after the 
initiation of IFX therapy the probability of still receiving IFX was between 61% [9] to 85% [18].
2. Probability of continuing infliximab therapy when combined with immunomodulator use
Five of eleven studies [10,12,14,16,17] subgrouped their patients by concomitant 
immunomodulator use and consistently showed that the probabilities of continuing IFX 
therapy in patients with prolonged immunomodulator use (i.e. longer than 6 months) were 
higher than for patients on IFX monotherapy (Fig. 2B).
3. Probability of continuing adalimumab therapy at 1, 2, and 3 years
Almost all patients following ADA had previously been exposed to IFX. The ADA starting 
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=IFX without IM or IM<6 months
=IFX+ >6 months IM
-
Fig. 2. Summary of probabilities of continuing infliximab at 1, 2, and 3 years after initiation. Plots display the 
probabilities of continuing infliximab therapy in included studies. The upper panel (A) shows the results of the 
entire cohort and the lower panel (B) shows the results of sub cohorts on either infliximab monotherapy or short 
combination therapy (white dots) vs. prolonged combination therapy (dark grey). 
IFX: infliximab, IM: immunomodulator.
doses were weight-dependent, but there was no uniformity between the two studies. Dose 
escalation, interval shortening, and concomitant immunomodulator use were allowed in 
both studies. A year after initiation of ADA therapy the probability of still receiving ADA was 
between 50% [20] to 85% [19].
Two years after the initiation of ADA therapy the probability of still receiving ADA was 
between 50% [20] to 79% [19]. The follow-up in the Rosh study [19] was sufficiently long to 
also report the 3-year probability: 79%.
DISCUSSION
This review of real-world evidence studies confirms the long-term therapeutic benefit of 
anti-TNF agents in diverse cohorts of pediatric patients with luminal CD. The probability 
of still receiving IFX 3 years after initiation exceeded 50% in all cohort studies, despite the 
fact that the majority of patients had previously failed on first line induction or maintenance 
therapy. Patients with concomitant immunomodulator use for 6 months or longer had 
higher probabilities of continuing IFX therapy 3 years after initiation than patients on IFX 
monotherapy. This suggests that the durability of IFX is enhanced in combination therapy. 
The limited number of time-to-event studies in patients on ADA therapy prevented us from 
drawing definite conclusions about the long-term efficacy of ADA. The fact that the patients 
following ADA therapy had previously been exposed to anti-TNF implies that the long-term 
efficacy may be better in anti-TNF naive patients.
Comparison with other studies
We report the first systematic review to incorporate summary time-to-event data to evaluate 
the long-term efficacy of anti-TNF agents in pediatric CD. To date, there have been two 
systematic reviews on the short-term efficacy of anti-TNF agents in pediatric patients, one 
focusing exclusively on IFX [21] and a second exclusively on ADA [22].
Li and colleagues [21] included three RCTs and 19 prospective cohort studies comparing IFX 
with other therapies (including ADA and exclusive enteral nutrition), and defined induction 
of endoscopic remission by 14 weeks and maintenance of endoscopic remission at 6 months 
as their outcomes of interest. Dziechciarz and colleagues [22] were mainly interested in the 
proportion of patients with remission at 4 and 12 weeks after the first dose of ADA, and the 
proportion of patients who maintained remission throughout the first year. They included 
one RCT and 13 observational studies, which were classified as case series; among these 
studies, we considered two of these to be retrospective cohort studies [19,20]. Similar to our 
study, they also concluded that there is a need for more high-quality evidence on the efficacy 
of ADA in pediatric CD.
Strengths and limitations
Although the current method provides a means of analyzing time-to-event outcomes for 
individual studies, it relies solely on published data for systematic reviews. For example, 
it was not possible to include all relevant studies because the outcome of interest was 
sometimes missing from the study report. Similarly, this method cannot correct for flaws 
in the design of the primary studies, such as post hoc exclusion of patients or failure to 
apply the intention-to-treat principle. In addition, different definitions of secondary loss of 
response may have affected the comparability of the outcome of interest between studies.
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Despite these limitations, real-world evidence studies surely complement the findings from 
RCTs by providing valuable information on treatment practices and patient characteristics 
among unselected patients. When individual participant data (IPD) is unavailable, the 
analysis of time-to-event outcomes is an appropriate alternative.
Trough levels and antibody measurements were not routinely assayed in the studies under 
review, but rather on a reactive basis when patients had secondary loss of response. In a recently 
published RCT in pediatric patients with luminal CD, it was shown that proactive measurement 
of ADA trough levels improved treatment efficacy up to 72 weeks after initiation [23]. These 
findings are of importance to further optimize the durability of anti-TNF agents in children who 
are known to be underdosed when standard regimens are applied [24].
Implications for pediatric practice
The benefits of concomitant immunomodulator use must be balanced against the increased 
risks of prolonged combination therapy, particularly lymphoma risk with thiopurines. No 
such risk has been detected when low-dose methotrexate is administered once weekly as an 
immunomodulator. Stopping concomitant immunomodulation could be considered 6–12 
months after initiation provided that IFX trough levels are in range and the patient is in 
clinical and biological remission.
Conclusion
This review of real-world evidence studies confirms the long-term therapeutic benefit of IFX 
therapy in children with luminal CD who failed first line therapies. Our findings suggest that 
combination therapy with an immunomodulator prolongs the durability of IFX therapy. More 
robust data on ADA therapy are necessary before we can draw definite conclusions about its 
long-term efficacy.
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